The obesity drug pipeline is stacked. As of April 2026, there are five FDA-approved GLP-1 medications for weight management, and at least six more serious contenders are in Phase 2 or Phase 3 trials. If you're wondering what's coming next — and whether you should wait — here's the complete rundown.
Currently Approved (April 2026)
Before we look ahead, here's what's already on the market:
- Wegovy (semaglutide 2.4 mg injection) — Novo Nordisk, approved June 2021, ~15% weight loss
- Zepbound (tirzepatide injection) — Eli Lilly, approved November 2023, ~22.5% weight loss
- Foundayo (orforglipron oral tablet) — Eli Lilly, approved March 2026, ~12.4% weight loss
- Oral Wegovy (semaglutide 50 mg tablet) — Novo Nordisk, approved February 2026, ~16.6% weight loss
- Saxenda (liraglutide injection) — Novo Nordisk, approved 2014, ~5-8% weight loss (largely superseded)
That's the baseline. Now here's what's coming.
The Full Pipeline at a Glance
| Drug | Company | Mechanism | Weight Loss | Form | Phase | Earliest Approval |
|---|---|---|---|---|---|---|
| CagriSema | Novo Nordisk | GLP-1 + amylin | 22.7% | Weekly injection | NDA filed | Oct 2026 |
| Retatrutide | Eli Lilly | GLP-1/GIP/glucagon | 28.7% | Weekly injection | Phase 3 | 2027–2028 |
| Survodutide | Boehringer Ingelheim | GLP-1/glucagon | 18.7% | Weekly injection | Phase 3 | 2028 |
| Amycretin (zenagamtide) | Novo Nordisk | GLP-1 + amylin | ~22% | Oral + injectable | Phase 2 | 2029–2030 |
| Aleniglipron | Structure Therapeutics | GLP-1 (oral small molecule) | 16.3% | Daily oral pill | Phase 2/3 | 2028–2029 |
| Monthly injectables | Various | Long-acting GLP-1 | TBD | Monthly injection | Phase 1-2 | 2029+ |
1. CagriSema — Closest to Market
CagriSema (cagrilintide + semaglutide) is the nearest to approval. Novo Nordisk filed its NDA in December 2025, and the FDA decision is expected around October 2026. At 22.7% weight loss, it matches Zepbound's efficacy with a different mechanism (amylin instead of GIP). The expected premium pricing ($1,500+/mo) may limit its appeal vs. Zepbound's LillyDirect pricing. Read our full CagriSema guide for details.
2. Retatrutide — The Efficacy King
Eli Lilly's triple agonist is in Phase 3 (the TRIUMPH program) and produced 28.7% weight loss in Phase 2 — the most ever recorded. It adds glucagon receptor activation to the GIP/GLP-1 combination, driving liver fat reduction and increased energy expenditure. NDA filing expected late 2026 or 2027, with approval possible in 2027–2028. This would be Lilly's third obesity drug. See our complete retatrutide guide.
3. Survodutide — Boehringer's Dual Agonist
Survodutide is a GLP-1/glucagon dual agonist from Boehringer Ingelheim (partnered with Zealand Pharma). Phase 2 results showed 18.7% weight loss at the highest dose over 46 weeks. It's currently in Phase 3 trials with results expected in late 2026. The glucagon component, like retatrutide, drives significant liver fat reduction — Boehringer is pursuing both obesity and MASH indications. Earliest approval: 2028.
Survodutide is notable because Boehringer Ingelheim is not currently in the obesity space, making this a new entrant that could increase competition and drive prices down.
4. Amycretin (Zenagamtide) — Novo's Next Oral Option
Amycretin is Novo Nordisk's oral GLP-1/amylin co-agonist. Think of it as CagriSema's mechanism in pill form. Phase 2 data showed approximately 22% weight loss, which would make it the most effective oral obesity drug in development. Novo is advancing both oral and injectable formulations. However, amycretin is still in Phase 2, placing its earliest approval at 2029–2030.
If amycretin delivers on its promise, it could eventually combine Foundayo-level convenience (oral) with CagriSema-level efficacy (22%+).
5. Aleniglipron — Another Oral Small Molecule
Structure Therapeutics' aleniglipron is an oral non-peptide GLP-1 receptor agonist — the same drug class as Foundayo but from a different company. Phase 2 results showed 16.3% weight loss at the highest dose, positioning it between Foundayo (12.4%) and injectable semaglutide (15%). Phase 3 trials are expected to begin in H2 2026. Earliest approval: 2028–2029.
Aleniglipron matters because competition in the oral small-molecule GLP-1 space will eventually put pressure on Foundayo's pricing and push the entire category forward.
6. Monthly Injectables — Reducing Treatment Burden
Several companies are developing once-monthly GLP-1 formulations that would reduce injection frequency from weekly to monthly. These are mostly in Phase 1-2 and won't reach the market before 2029 at the earliest, but they represent an important convenience improvement — especially for patients who find weekly injections burdensome.
What This Means for Patients Right Now
With this many drugs in the pipeline, it's tempting to wait. Don't. Here's why:
- CagriSema is the only pipeline drug that could be available within 12 months, and even that's not guaranteed
- Retatrutide is 1-2 years away — and Phase 3 trials occasionally fail or show lower efficacy than Phase 2
- Everything else is 2-4+ years from approval
- Obesity is a chronic disease with cumulative health effects. Every month you delay treatment, cardiovascular and metabolic risks continue to accumulate
Start with what's available today. Foundayo at $149/month and Zepbound at $299+/month are here right now. You can always switch to a newer drug when it arrives. For help choosing, see our Foundayo vs Zepbound comparison.
Bottom Line
The GLP-1 pipeline is deeper than it's ever been. Within the next two years, we could see drugs delivering 22-29% weight loss across multiple mechanisms. Prices will come down as competition intensifies. But none of that helps you today. If you qualify for treatment, start now — the drugs already available are highly effective, and the pipeline drugs will be there when they arrive. We'll update this guide as clinical results emerge and FDA decisions are made.
Sources
- Novo Nordisk. "CagriSema NDA Filing." December 2025.
- Jastreboff AM et al. "Retatrutide Phase 2." NEJM. 2023.
- Boehringer Ingelheim. "Survodutide Phase 2 Results." ObesityWeek 2024.
- Novo Nordisk. "Amycretin Phase 2 Data." Research pipeline update, 2025.
- Structure Therapeutics. "Aleniglipron Phase 2 Results." 2025.
- FDA. Approved Drug Products database. April 2026.